A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease

Trial Profile

A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Acronyms HAEM 4174
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 11 Oct 2017 According to a Global Blood Therapeutics media release, data were presented at the Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference in London.
    • 28 Jun 2017 According to a Global Blood Therapeutics media release, based on the data from this study, European Medicines Agency (EMA) has determined that GBT440 for the treatment of sickle cell disease is eligible for its Priority Medicines (PRIME) program.
    • 13 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top